Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. This trade represents a 13.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Peetz also recently made the following trade(s):
- On Monday, August 10th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $98.92, for a total value of $1,978,400.00.
- On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $122.27, for a total transaction of $2,445,400.00.
Mirum Pharmaceuticals Price Performance
NASDAQ MIRM opened at $100.90 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12 month low of $63.23 and a 12 month high of $130.00. The stock has a market cap of $6.55 billion, a price-to-earnings ratio of -6.93 and a beta of 0.49. The company’s 50 day moving average is $109.09 and its two-hundred day moving average is $101.73.
Hedge Funds Weigh In On Mirum Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its holdings in Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $691,672,000. California State Teachers Retirement System boosted its position in shares of Mirum Pharmaceuticals by 12,542.7% during the 2nd quarter. California State Teachers Retirement System now owns 5,622,989 shares of the company’s stock valued at $658,283,000 after acquiring an additional 5,578,513 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Mirum Pharmaceuticals in the second quarter valued at $513,945,000. Finally, Vanguard Group Inc. grew its holdings in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after purchasing an additional 50,720 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on MIRM shares. Wolfe Research assumed coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price objective for the company. Citigroup reissued a “market outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 27th. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, TD Cowen lowered their target price on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $137.31.
View Our Latest Stock Analysis on MIRM
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Featured Stories
- Five stocks we like better than Mirum Pharmaceuticals
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
